2025: From Insight to Impact
A Year of Partnership and Progress Looking back at 2025, we find ourselves reflecting not just on the milestones we’ve marked, but on the evolving landscape of our industry. This year has been defined by complexity and opportunity in equal measure. For the biotech community, the challenge has remained consistent: how to navigate the intricate […]
The Evolving IPF Landscape
What Nerandomilast Means for Future Antifibrotic Development In recent blogs we have reflected on the promise shown by the orally-delivered preferential PDE4B inhibitor, nerandomilast, now approved by the FDA for the treatment of IPF. After many years of negative clinical data from many programs, and frustration within the field, this molecule now shows promise as […]
Inhaled Therapies for IPF – an update
In a recent blog we reflected on key presentations at the ERS relating to pulmonary fibrosis, including the promise shown by the orally-delivered preferential PDE4B inhibitor, nerandomilast, now approved by the FDA for the treatment of IPF. However, the Fibroneer programme with nerandomilast further served to emphasise the challenge faced when attempting to use new […]
Reflections from ERS 2025
From a Pulmonary fibrosis perspective, the ERS meeting in Amsterdam (27 September to 1 October, 2025) provided a combination of hope, challenge and satisfaction for the TherapeutAix team. Hope was provided by the updates on the Fibroneer trials of Boehringer Ingelheim’s (BI) preferential PDE4B inhibitor, nerandomilast. After many years of negative clinical data and frustration […]
Society for Medicines Research (SMR) Meeting on Women’s Health
Darcey Black, Translational Science Director at TherapeutAix, will be attending and co-chairing a session at the forthcoming SMR Meeting on Women’s Health, taking place at Friends House, London, on 17th June. The one-day meeting will bring together a panel of women’s health experts comprising leading researchers from academia, biotech and pharma. They will describe the […]
Biking for Action Medical Research
Our co-founder and Director of Translational, Darcey Black, is planning to take part in the BiotechBikers “Catalyst” Charity Event, a 250-mile cycle ride from London to Bruges, on 8th to 10th May 2025. The event will raise funds for Action Medical Research. Action Medical Research (www.action.org.uk) is the leading UK charity dedicated to funding […]
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update highlights the untapped potential of inhaled drug delivery in the treatment of IPF, a disease with poor prognosis and limited treatment options. It’s worth contrasting this therapeutic scenario with that […]
The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite high unmet clinical needs, the current standard of care—antifibrotic therapies nintedanib and pirfenidone—offers only modest benefits, with ongoing side effects that are a significant burden to patients. In our latest […]
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our reflections. Despite the virtual format there was still a huge amount of information, so we have decided to limit this to just 4 take-home messages that we came away with. What’s next in COPD? When working with […]